Medical Oncologist
When treatment stops working
Being Told 'There Are No More Options': — Is That Really True?
Hearing that your treatment has stopped working is one of the hardest moments in a cancer journey. But resistance to one treatment is not the same as running out of options. Most patients have more paths to explore than they realise.
Medically reviewed by Dr. Bharati Devi Gorantla, Medical Oncologist, MBBS · MD · DM (Adyar, Chennai) · ECMO · MRCP SCE (UK) · Last reviewed August 2026
- Resistance is biological — Cancer cells adapt to avoid drugs. This is a property of the disease, not something you caused.
- Options are rarely truly exhausted — Second-line, third-line, and clinical trial options exist for most cancer types, including at advanced stages.
- Re-testing can open new doors — A tumour can change after treatment. Fresh molecular testing sometimes reveals targets that were not there before.
- A second opinion is always reasonable — Asking another specialist to review your case at any point is normal and accepted in cancer care.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Being told there are no more options usually means this particular treatment has stopped working — not that all options are gone. Resistance to one drug or regimen is a biological event. Your oncologist should be reviewing second-line options, molecular re-testing, and clinical trials before reaching that conclusion.
What do these terms actually mean?
- Treatment resistance
- When cancer cells develop ways to survive a drug that was previously working. It happens because cancer cells mutate constantly, and the cells that avoid the drug are the ones that multiply.
- Progression
- When scans or tests show the cancer is growing or spreading despite treatment. Confirmed progression is what triggers a formal review of the treatment plan.
- Next-line therapy
- The treatment used after the first one stops working. Most treatment plans are designed with a first-line, second-line, and sometimes third-line option from the start.
- Molecular re-testing
- Analysing a fresh tissue or blood sample to see how the tumour has changed since the original diagnosis or since treatment began. Resistance can create new mutations that open new treatment targets.
- Clinical trial
- A research study testing a treatment not yet in routine use. Eligibility for a trial is not the same as having no standard options left — trials often run alongside or just after standard care.
Why does cancer stop responding to treatment?
Cancer is not a fixed population of identical cells. It is billions of cells, each slightly different, changing constantly through mutation.
When treatment works, it kills the most vulnerable cells. Some cells, even very few, may already carry mutations that let them survive. Those cells multiply. Over time they become the dominant population, and the treatment that worked before no longer controls them.
This is resistance — and it is the nature of the disease, not a failure of treatment or of you. Understanding it shifts the question from 'why did this stop working' to 'what does this tumour look like now, and what targets does it have'.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What should happen after a treatment stops working?
Confirm progression
Progression should be confirmed on scans or by a measurable marker before treatment is changed. A single poor result is not enough to act on alone.
Multidisciplinary team review
Complex or progressive cases should be discussed in a team meeting involving oncologists and radiologists before next steps are decided. Ask whether your case has been or will be reviewed this way.
Consider molecular re-testing
A fresh biopsy or liquid biopsy can reveal changes in the tumour since treatment began. Some mutations that appear at resistance are targetable by drugs not used in first-line treatment.
Review next-line treatment options
For most cancer types, NCCN, ASCO, and ESMO guidelines describe what to consider when first-line treatment fails. Ask your oncologist which of those options applies to your specific cancer and stage.
Check clinical trial eligibility
Trials are frequently available to patients whose disease has progressed on standard treatment. Ask specifically whether any trials are open for your cancer type — this is rarely offered unless you ask.
Discuss goals of care openly
If keeping the cancer stable long-term, rather than trying to eliminate it, is the realistic aim, that changes how you should evaluate each option. This conversation should happen clearly, not be avoided.
What should you ask at your next appointment?
Ask three specific questions. Has my tumour been re-tested since this treatment stopped working? What do the guidelines say about second-line or third-line treatment for my cancer type? Have I been assessed for any clinical trials?
If all three questions have been addressed and no further disease-directed treatment is recommended, the conversation shifts to what can still be achieved — managing symptoms, maintaining quality of life, and controlling the disease where possible. That is a legitimate goal, and one that deserves as much care and planning as any other.
A second opinion at this stage is reasonable and widely accepted. Your current team can usually facilitate a referral, or you can approach another centre directly. A second specialist reviewing the same case sometimes identifies an option that was not in view before.
Explore 39 more Monitoring, Resistance & Long-Term Response topics
Resistance, Progression & Next Lines
- Being Told 'There Are No More Options': Is That Really True?
- Brain Metastases on Targeted Therapy: Does Your Drug Reach the Brain?
- Can You Continue the Same Drug After Progression?
- Combination Therapy to Overcome Resistance
- Do You Need Another Biopsy When the Cancer Progresses?
- Histologic Transformation: When Lung Cancer Changes Type
- How to Emotionally Process a Progression Scan
- Leptomeningeal Disease: Symptoms, Diagnosis and Treatment
- Life After ALK Inhibitor Resistance: Sequencing Your Options
- MET Amplification and Other Bypass Resistance Mechanisms
- Oligoprogression: When Only One or Two Spots Grow
- Primary vs Acquired Resistance: Two Very Different Problems
- Should You Change Hospitals After Progression?
- What Happens After Osimertinib Stops Working?
- What Is Sequencing and Why the Order of Drugs Matters
- Why Does Targeted Therapy Stop Working? The Biology of Resistance
Long-Term Response, Stopping & Survivorship
- Am I Still a Cancer Patient? Identity After Long-Term Response
- Bone Health, Heart Health and Late Effects to Monitor
- Can You Ever Stop Targeted Therapy If the Cancer Is Gone?
- Drug Holidays: Are Planned Breaks Safe?
- Follow-Up Schedule After Stopping Targeted Therapy
- How Long Do You Have to Stay on Targeted Therapy?
- Long-Term Effects of Taking a TKI for 5 or 10 Years
- Restarting Treatment After a Break
- Treatment-Free Remission in CML: Who Can Stop Their TKI?
- Your Survivorship Care Plan: What Should Be In It
Monitoring, Scans & Response Assessment
- Are Tumour Markers Reliable on Targeted Therapy?
- Complete Response, Partial Response, Stable Disease: What Each Means
- Do I Need Regular Brain MRIs on Targeted Therapy?
- How Doctors Measure Whether Targeted Therapy Is Working
- How Often Will I Need Scans on Targeted Therapy?
- How to Read a CT or PET Scan Report Without Panicking
- Is 'Stable Disease' Good News or Bad News?
- Scanxiety: How to Get Through the Wait for Scan Results
- Tumour Flare and Pseudoprogression: When Growth Isn't Really Growth
- Understanding PFS, OS and Median Survival Without Losing Hope
- What Happens at a Follow-Up Visit: A Walk-Through
- Which Blood Tests Are Repeated Every Month and Why
- ctDNA Monitoring: Can a Blood Test Predict Progression Early?
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does 'no more options' always mean the end of treatment?
Usually not. It most often means that the standard treatments for your cancer type have been tried and have not controlled the disease. Before that conclusion is final, your oncologist should have reviewed whether molecular re-testing has identified new targets, whether second-line or third-line options exist within guidelines, and whether any clinical trials are open to you. If you are not sure whether all of those steps have been taken, it is reasonable to ask directly.
Is it worth getting a second opinion at this point?
Yes. A second opinion from a specialist in your cancer type can confirm that the plan is the best available, or identify an approach that was not considered. You can ask your oncologist to arrange a referral, or contact another centre directly. Most oncologists support this — it is a normal part of care when the situation is complex, and it is not a sign of distrust toward your current team.
What is a liquid biopsy and can it help when treatment has failed?
A liquid biopsy analyses fragments of tumour DNA circulating in the blood, without requiring a new tissue sample. It can detect mutations present at the point of resistance, including changes that may have appeared after treatment began. Whether it changes what is available to you depends on your cancer type and what the test finds. Ask your oncologist whether this has been done or whether it would be useful in your situation.
Are clinical trials only for people who have run out of other choices?
No — this is a common misunderstanding. Some trials are specifically designed for patients whose disease has progressed on standard treatment, but that does not make them inferior care. Trials are how many effective treatments first become available, and being in a trial means receiving a treatment with scientific rationale behind it and close monitoring throughout. Ask your oncologist whether any trials are currently open for your cancer type and stage.
What if the cancer is very advanced — does any of this still apply?
Yes. Advanced stage does not automatically mean there are no options, though it does shape what is realistic to aim for. Even in advanced disease, next-line treatments, trials, and symptom-focused care can extend life and improve its quality. The honest conversation to have with your oncologist is about what each option is expected to achieve and what the likely side effects are — so that you can decide together what is worth trying for you.
How do we know when treatment is causing more harm than good?
This is one of the most important and most avoided conversations in oncology. Treatment is generally worth continuing when it is controlling the disease or its symptoms and the side effects are tolerable. It becomes harder to justify when it is not slowing the disease, side effects are severe, and quality of life has significantly worsened. A palliative care specialist — who works alongside your oncology team, not instead of them — can help you think through what each option is realistically offering and what matters most to you.